But why the considerable momentum - there has to be more to it.
Based on the following stats, would anyone in the right mind invest in UK medical sector atm without incredibly thorough research...I searched on a data source provided by AJB. The following surprised me:
Of firms in the sector on YTD performance:
20/97 beat FTSE100
55/97 made > 15% loss
34/97 made > 40% loss
What a total and utter wealth destroyer in the main this year for many I suspect.
OXB sits number 2 as the best performer league - but crikey you can strike lucky but what on earth has been going on elsewhere then.
A landing zone in a mine field possibly in 2024 :) nai etc |
Oh well,Harry's and my post crossed and his table is both a good deal more informative and up to date.The 325th spot as of the close of business yesterday is around £550m meaning OXB would have to get to 525p to be promoted. |
The FT250 table included by philh75 is a very functional list that can be adjusted online by market cap.As things stand Tritax and Henderson Europe are currently occupying the important 325th position that is necessary to gain promotion to the FT250 and they both have a market cap in the mid £570m region.OXB has 105,36m shares in issue so-as a rule of thumb-a price of around 546p would suggest OXB would currently be promoted.There's a month to go to the next review but what is striking is the recent momentum in the OXB share price and the fact that studies show that shares invariably move sharply ahead of inclusion in an index,presumably as trackers buy in anticipation.Ceres did just that ahead on the most recent review but has fallen sharply thereafter and now has a market cap below OXB. |
Sort of Phil. An easier page to read is which is updated every Friday.
Yesterday we closed at 347th place of those who qualify (you can see non-qualifying AIM stocks greyed out there) and the Friday before we were 357th place.
So knock off 100 for the FT100 and "technically" last last week we were just outside the 250 and this week just in it, but the way it actually works you have to be just above 325th place on the review date to push someone out below.
I don't want to curse it, but I think this little trend (all the traders seem to like trends) and the very good possibility that we will be back in the Morgan Stanley index in 8 working days means that 4 weeks today I will be very pleased to be calling OXB a FTSE250 stock again.
If OXB get some good news out in the next month I'd be all but certain, though I am pretty confident OXB will be readmitted after the 22nd with or without it. |
The way I read it (which may be wrong) is the last entry currently in the Ftse250 is CBG with a market cap of £551m, so oxb at £6 (£630m) has a very good chance yes. But obviously depends on other competition at the time of the review, so whether that mcap requirement has shifted upwards. |
With a MCap of £443m atm, with a seeming large number of firms with higher (in some cases much higher) mcaps, why is there belief that we have a better chance of FTSE250 entry. I know it has been repeated a number of times, but I think someone needs to show a list and who is actually ahead of us for the full context.
For example is even an share price of six quid enough for this time - I remain very unclear and would like more analysis of the data points.... |
Just been watching the cinema film about Trump's early days..quite some life he has led.
We powered through 4.40 ...this is starting to really motor again here... |
Worth keeping an eye on Milei/Argentina. It may be the start of something broader, particularly if Musk, sorry, Trump, gets in. |
We’re all singing from pretty much the same song sheet here.
The real conundrum is the quality of the candidates that are being presented to democracies worldwide.With the rigours of social media,personal safety etc,who the hell wishes to be a politician other than self-opinionated narcissists and ideologues. |
How many "workers" in the UK receive a cheque each month or if they have an emergency write out a cheque? Not many I suggest. |
I hate my phone keyboard |
March, notatch. |
Read the thread to get an idea. You'll need to go back to Match to get the full story. |
is this a good share |
FT250 inclusion now feels like a probability rather than a possibility. |
So the auction trade to end there was both 12 month highest intraday and closing price and on good volume.
I think that one is up there with seeing a star in the east wrt the MS index and then the FT250 readmissions. |
Apparently you need to be paid by cheque once a month to be a working person. |
Without going into politics, it appears Sir Starmer's very prestigious previous life is now causing problems in his current role as Prime Minister. |
“Speaking to broadcasters in Samoa, Keir Starmer said he would not use the term-‘working people’-for people who had income from assets such as shares or property. “They wouldn’t come within my definition,” he said. Downing Street hastily clarified that the prime minister did not mean people who owned small amounts of, for example, stocks or shares.”
What with supermarkets expecting one to check out your purchases (and in due course maybe stack the shelves)it seems inevitable that unworthy folk like me will be dragooned into sweeping the roads.I deserve no better.I seem to remember from my university politics course that similar sentiments were expressed by the Bolsheviks and during the period of the Third Reich. |
 Unknown unknowns Dom.
I would guess that Boston / Bedford has been Seb's highest priority as losing that late stage work (with Homology shutting up shop) would be so difficult to make up for - even with a lot of very early stage AAV work.
They seem to have done very well to react, with the impairment charge now addressed and that site becoming a LentiVector hub this year, but it can't have been easy.
I think we can all guess the likely reason why the Oxford and Boston business units are combined in the figures, and that's because one has been carrying the other with OXB not wanting to admit by how much, but my upside view on that would be to note that once the US site begins to contribute significantly then happy days - and that is simply a matter of time.
I'm pretty confident that France will contribute this year as they seem to be doing very well with Geovax and other work, but I think OXB have mentioned a few times now that whilst their LentiVector presence in the market is mature and very well known within the industry, their AAV services are not. I'm sure they have been working very hard to sort that out - as noted by 42% of our new work being AAV in the recent presentation. |
More effort needed to promote Boston part? Big pharma 'feel safer' buying in the good ole US of A. |
Reading my newsfeed this morning I was distracted by this:-
So Roche deepening their existing tie-up with Dyno.
What are Dyno? basically a bespoke AAV company which tailors vectors for specific applications using AI.
It made me ponder what Dyno can do for Roche with their AAV and AI which OXB couldn't do for a different partner with our AAV and our AI
I suspect the answer is not a lot, but I don't know for sure.
Obviously it's natural / logical for Roche to stay with the vector they selected in 2020 when OXB didn't have an AAV to offer, but surely potential here now for OXB to offer similar tie-ups to others?
Appreciate that we are pure CDMO these days, but the D there is of course development.
From all we have been told the Homology AAV was a very good one (hence the amount of cash we were willing to spend) and it is now improved further by OXB tech.
It's something we would never know about until it happened, but we are intimately involved with Novartis and BMS linked to our LV, so surely a similar AAV tie-up with a major is on the cards at some point. |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
